Weight loss is rarely linear, and plateaus are common and normal during treatment
10.1007/s00125-003-1103-y
I am curious though, in the, in the same vein as you brought up MS, what are we seeing in terms of neurological health and the benefits there
The most extensively studied compounds are exenatide (Byetta [Amylin Pharmaceuticals, San Diego, CA], which has been approved by the US Food and Drug Administration [FDA] for the treatment of type 2 diabetes), liraglutide (Victoza [Novo Nordisk, Princeton, NJ], which has been submitted to the FDA for approval), sitaglitptin (Januvia [Abbott Laboratories, Abbott Park, IL], which has been approved by the FDA for type 2 diabetes), and vildagliptin (Galvus [Novo Nordisk, Princeton, NJ], which has been submitted to FDA)
Ive switched them to Zepbound and havent had the same issues
The study used 120 minutes of moderate-intensity exercise per week